Federico Rossari
Impact in
- Hematology top 10%
- Chronic Myeloid Leukemia Treatments
- Genetics top 10%
- Chronic Lymphocytic Leukemia Research
- Inflammatory Bowel Disease
Papers in
- Oncology 12
- Cancer Immunotherapy and Biomarkers 4
- Colorectal Cancer Treatments and Studies 3
- CAR-T cell therapy research 3
-
- Single-cell and spatial transcriptomics 1
- Co-authors
- Enrico Orciuolo (2 shared papers)Filippo Minutolo (1 shared paper)Gabriele Buda (1 shared paper)Luigi Naldini (4 shared papers)Nadia Coltella (5 shared papers)Peter Angel (1 shared paper)Francesca Sanvito (1 shared paper)Melania Cusimano (2 shared papers)
- Journals
- Targeted Oncology (2 papers)Annals of Oncology (2 papers)Science Translational Medicine (2 papers)Trends in Molecular Medicine (1 paper)EMBO Molecular Medicine (1 paper)
- Partner nations
- ItalyGermanySouth Korea
In The Last Decade
Federico Rossari
12 papers receiving 423 citations
Federico Rossari's Hit Papers
Peers
Comparison fields: 5 of 67
- Hematology 122
- Genetics 88
- Oncology 145
- Immunology 58
- Molecular Biology 179
Countries citing papers authored by Federico Rossari
This map shows the geographic impact of Federico Rossari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Federico Rossari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Federico Rossari more than expected).
Fields of papers citing papers by Federico Rossari
This network shows the impact of papers produced by Federico Rossari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Federico Rossari. The network helps show where Federico Rossari may publish in the future.
Co-authors
The 25 scholars most cited alongside Federico Rossari, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Past, present, and future of Bcr-Abl inhibitors: from chemical development to clinical efficacy Hit paper breakdown → | 2018 | 254 |
| 2 | 2022 | 54 | |
| 3 | 2020 | 47 | |
| 4 | 2019 | 36 | |
| 5 | 2023 | 15 | |
| 6 | 2023 | 9 | |
| 7 | 2023 | 6 | |
| 8 | 2024 | 3 | |
| 9 | 2023 | 2 | |
| 10 | 2025 | 1 | |
| 11 | 2018 | 1 | |
| 12 | 2023 | 1 | |
| 13 | 2024 | 0 | |
| 14 | 2024 | 0 | |
| 15 | 2024 | 0 | |
| 16 | 2025 | 0 | |
| 17 | 2025 | 0 | |
| 18 | 2024 | 0 | |
| 19 | 2024 | 0 |
About Federico Rossari
Federico Rossari is a scholar working on Oncology, Molecular Biology, Hepatology, Surgery and Epidemiology, having authored 19 papers that have together received 429 indexed citations. Recurring topics across this work include Hepatocellular Carcinoma Treatment and Prognosis (6 papers), Cancer Immunotherapy and Biomarkers (4 papers), Colorectal Cancer Treatments and Studies (3 papers), CAR-T cell therapy research (3 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (3 papers), Liver physiology and pathology (2 papers), Immunotherapy and Immune Responses (2 papers) and Single-cell and spatial transcriptomics (1 paper). The work is most often cited by research in Hematology (122 citations), Genetics (88 citations), Oncology (145 citations), Immunology (58 citations) and Molecular Biology (179 citations). Federico Rossari has collaborated with scholars based in Italy, Germany and South Korea. Frequent co-authors include Enrico Orciuolo, Filippo Minutolo, Gabriele Buda, Luigi Naldini, Nadia Coltella, Peter Angel, Francesca Sanvito, Melania Cusimano, Eleonora Albano and Renato Ostuni. Their work appears in journals such as Targeted Oncology, Annals of Oncology, Science Translational Medicine, Trends in Molecular Medicine and EMBO Molecular Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.